NCT06520540 - HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

December 30, 2024

Conditions

Glucagon-Like Peptide-1 Receptor Agonists

Interventions

DRUG

HDM1002 100 mg QD 12weeks

Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)

DRUG

HDM1002 200 mg QD 12weeks

Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)

DRUG

HDM1002 400 mg QD 12weeks，Q 2W for titration

Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration

DRUG

HDM1002 400 mg QD 12weeks，Q 3W for titration

Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration

DEVICE

Placebo

Trial Locations (1)

HDM1002, Shanghai

All Listed Sponsors

lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY